Figure 2
Figure 2. Surface phenotype of B cells from healthy control donors and XLP patients. (A) PBMCs from a healthy control donor and a representative XLP patient, XLP5, were stained with anti-CD20 mAb, and the frequency of B cells in the lymphocyte population determined (leftmost panels; frequency shown as percentage). In the remaining panels, purified CD20+ B cells were dual-stained with mAbs specific for CD27 and either CD10, IgD, IgM, IgG, or IgA to obtain the FACS profiles shown. (B) Summary of B-cell surface phenotype data obtained from 6 healthy control donors and 4 XLP patients (XLP5-8). Results are expressed (left to right) as the percentage of PBMCs that were CD20+ B cells, and the percentage of CD20+ B cells that had the transitional, naïve, or memory cell phenotypes shown. The mean value for each group is denoted by the horizontal bar.

Surface phenotype of B cells from healthy control donors and XLP patients. (A) PBMCs from a healthy control donor and a representative XLP patient, XLP5, were stained with anti-CD20 mAb, and the frequency of B cells in the lymphocyte population determined (leftmost panels; frequency shown as percentage). In the remaining panels, purified CD20+ B cells were dual-stained with mAbs specific for CD27 and either CD10, IgD, IgM, IgG, or IgA to obtain the FACS profiles shown. (B) Summary of B-cell surface phenotype data obtained from 6 healthy control donors and 4 XLP patients (XLP5-8). Results are expressed (left to right) as the percentage of PBMCs that were CD20+ B cells, and the percentage of CD20+ B cells that had the transitional, naïve, or memory cell phenotypes shown. The mean value for each group is denoted by the horizontal bar.

Close Modal

or Create an Account

Close Modal
Close Modal